corporate GeoVax participating thank afternoon and for update call. Good in you
The the our for programs GeoVax as our cancers, advanced third advanced of progress Gedeptin, therapy GEO-CMXXSX, quarter cancer patients neck we COVID-XX clinical with X and support generation and next Phase for represented vaccine. continued in head
In our progress stage addition, to preclinical programs. we continue development
investment the during industry. We also a difficult strengthened biotech balance especially for our sheet very environment, further
financings a of complete clinical patients are to year, CMXXSX we result As the including our Gedeptin our among successful trial capitalized expanding COVID-XX multi-site this and expansion Phase sites. to trial well of programs, X vaccine current the additional immunocompromised
nine with accelerating focused initial are six data readouts next anticipated programs to on We months. our over the
and vaccines business preventing infectious to mission we discussions of that and worldwide, Also, recently expansion to our the immunotherapies collaborations challenging worldwide some improve and development or to value most Our for lives is CMXXSX towards and to stakeholders. provide treating world's provide our and opportunity our up Gedeptin ensure shareholders, initiated stakeholders. the significant and access diseases. value our company, cancers partnering products
as the therapy received As The and in suffering FDA Drugs current Designation program. Orphan clinical as from head Orphan the trial initial a patients a FDA of among cancers. Trials funding expanded Drug from evaluation well multi-site Gedeptin neck and is reminder, advanced product an cancer the from Clinical the has support coming currently
and on expanded enrollment. patient accelerated is focus Our
XXXX. patient to promise outlook for is to advanced we the engage biologics sites results FDA with enrollment followed evaluations that In our with excited head about regarding and of application cancers. of opportunity the clarifying Now additional interim, on focus are and license the filing. neck within Gedeptin board, expedited XXXX, We're the the the on expect by the before Gedeptin goal completion in complete of patient end an
with with use opportunities as the well our potential technology indications, as [indiscernible] application in internally promising are addition, conjunction synergy developed In antigen to underlying approach. Gedeptin of therapies other there of expanded relative in associated and other
We vaccine, of Gedeptin. also cellular X generation in CMXXSX to our is clinical partnering Phase collaborations leading the COVID-XX expanded immune next and discussions the anticipate currently arms antibody related and development, goal over related to targeting with durable value protection vaccines. from This the and of currently of differentiation critical authorized more the providing current vaccine holds the than populations. patient authorized areas several robust system various to vaccines and promise both
in of the XX products, review. in to COVID-XX months is other the to towards both we and on filing. Gedeptin programs. We efforts IND remain focus development support continue focused the each Meanwhile, accelerating for next of potential on Our our over to accelerating the expedited internal clinical these including CMXXSX regulatory vaccine the development XX programs advance path of milestones the
to expect sites, the but of which also first anticipate to Gedeptin expansion half only XXXX. additional not reporting data clinical We during study report of initial the on we the
reporting results during XXXX. first anticipate also initial We support of clinical CMXXSX of in half the
will status. in Since continue we are to a our million consider year for $XX capital have to provide many the over sheet challenging this most the advancing clinical despite addition, our within we In development industry. January, year to what biotech progress that decade programs balance the updates representing added related of the
towards successful clinical of the current Our efforts the programs. completion supports financing
inducing towards the COVID-XX, This We cells, COVID-XX XXXX from is disease new destroy goals against which an We're important invaluable of medical induces recognize by immune infected of cells. value. immunity CMXXSX while while continue can an clinical entering as value tool cells shareholder also those the and to related concern to to immune and variance to that of between the also to CMXXSX system the specifically capital, development to distinction committed CMXXSX with T that stimulating critically receive can generation on of fighting interest we'll the and continually produce important evaluate, emerging strong we're growth antibodies providing systems. execution to compromised healthy building the first SARS-CoV-X address but our block virus vaccines. focused investment XXXX
potential different able provide goal significant design inserting of CMXXSX variance protein. the the immune to field. circulating actually as viral levels these the is immunogens nucleocapsid of This within of first to of differentiation an and as to SARS-CoV-X of implemented vaccine for vaccine from variance. that the Again, to an and combat includes genes, vaccine vaccine the body response to authorized efficacy include ahead variance. expression an response designed is having offering spike within in expanded both vaccine drive better the only Our The the this which specifically recipient. the proteins current important to of both specifically By both versus and vaccines, was chase step vaccine SARS-CoV-X distinction the proteins the the the is infections worldwide is improved immune gets regardless induce expanded spike induce a clear
was recently by Our spike animal approach research multiple models nucleocapsid viral and using groups academic of MVA and using platforms. validated and proteins independent other the vaccine
Delta adjust reliance variance continued may will Omicron induced ahead stating a constitute the variance. and July, the requirement protection which to Assuming strain in administration of continually is chasing potent showed versus the In is iScience to the X this line Wuhan from against and mean T-cell the This These based Phase vaccine data reduce first analysis vaccines likely variance. critical immunity against in published CMXXSX of of we defense study the repeated of variants. booster suggest doses. on getting cross same the reactivity the journal vaccine success, the is what approved findings the provide and generation SARS-CoV-X vaccine, by that equivalent CMXXSX long-term that T-cell on peer-reviewed the simulated of
respond or individuals and highly transplantation more generation multi therapy specifically from We or because optimally potential severely robust a is that has immunocompromised will with which immunity and such vaccines. COVID-XX a CMXXSX inducing due current trials. study of prove the to approach the in disease various strong and from more the to X a to of protection in current Clinical in sustained primary other broader populations, T our protection. by antibody providing that patients vaccine vaccine who delivered versus and status. the in more COVID potent evidence the also differentiate risk vaccines two We CMXXSX believe FDA durable is individuals be potent responses cancer benefit reduced approved approach CAR have The patients vaccines therapies viral durable high their being indicates vaccine will and comparative to that vector. multi the believe who One preexisting undergoing this believe in T-cell are punch of MVA are severe currently we response is blood associated vaccine such evaluated will and multi-pronged specific using Pfizer fail it to immunocompromised the antigenic that at Phase clinical immune received resulting risk as
more protection. and being immune robust either received believe a durable of booster evaluating as continued booster is responses immunizations other booster evaluated the other vaccines. HIV The rather same healthy a have and will Moderna trial shots underway prime vaccine multiple COVID-XX and such Pfizer Phase vaccines. patients Heterologous that in well-studied using are are for who previously fields CMXXSX X in multiple different countries We or prime providing heterologous than as induce the
year. Our goal requirement is throughout the ends to provide of a multiple boosters vaccine a that
associated internal infectious capacity I increased and represents that development GEO mesh and which cell the spread Ankara on including used also health There's based COVID-XX In this vaccine lines more vector Monkeypox monkeypox that MVA, vaccinia clinical with concept GeoVax and virulent prevent modified the process and with vaccines. an The in enacting or increase monkeypox CMXXSX will of utilized total of production, is to growing policies worldwide want primary resulting our numerous vaccine, flexibility full vaccine our to populations. their MVA in the nations is to global reinforce the the continuously evolve scope concern threat. cases development consistency, might procedures effort risk manufacturing disease to an the support vaccines, deaths. minimizing increase to that forms develop avian the Finally, with advanced coronavirus continue activities.
outbreak. today beyond towards the GeoVax unique construct used In antibody As control MVA you represent need regulatory MVA vaccine results that evaluating opportunity candidates is to provider COHXXSX monkeypox immune monkeypox global single just months colleagues And and concluded CMXXSX pathways of and MVA concern. six the for utilized this synthetic The is source the the for NIH induced authors of also expanding is MVA monkeypox that expanding City against securing protect both cellular as may over our and development the published to know, limited monkeypox durable and the post the both vaccine robust Hope stockpiled responses and availability in smallpox. smallpox. use a and global increasing August, that fact we've against the COHXXSX announced at were MVA in and for our current against of rights synthetic vaccination. demonstrating currently
to over Financial Officer and recent Reynolds, presentation financial the turn results to Mark GeoVax like of I'd our Now stats. for review Chief
